Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9221MR)

This product GTTS-WQ9221MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9221MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4243MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ11071MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ12726MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ13733MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ14415MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ4573MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ2924MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ10422MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2439821
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW